Andrew A. Hindman
CIK 1607965 · SVP, CHIEF FINANCIAL OFFICER · last filed 2022-11-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.50M
Companies
2
Total Filings
37
Lifetime Open-Market Net
-$2.20M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TBPH | SVP, CHIEF FINANCIAL OFFICER | 384,714 | $16.89 | $6.50M | -$716.2K | 16 | 2022-11-22 |
| Acorda Therapeutics, Inc. (ACOR) Delisted | Chief Business Officer | 130 | $0.66 | $86 | -$1.48M | 21 | 2019-03-12 |
Recent Filings · Page 3 of 4
37 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-11-07 | Acorda Therapeutics, Inc. (ACOR) Delisted | Tax (F) | −879 | -$17.8K | EDGAR |
| 2018-09-12 | Acorda Therapeutics, Inc. (ACOR) Delisted | Grant (A) | +2,300 | $0 | EDGAR |
| 2018-05-30 | Acorda Therapeutics, Inc. (ACOR) Delisted | Sell (S) | −42,615 | -$1.03M | EDGAR |
| 2018-05-15 | Acorda Therapeutics, Inc. (ACOR) Delisted | Tax (F) | −3,930 | -$95.7K | EDGAR |
| 2018-02-26 | Acorda Therapeutics, Inc. (ACOR) Delisted | Grant (A) | +5,742 | $0 | EDGAR |
| 2017-12-05 | Acorda Therapeutics, Inc. (ACOR) Delisted | Sell (S) | −817 | -$16.8K | EDGAR |
| 2017-05-17 | Acorda Therapeutics, Inc. (ACOR) Delisted | Sell (S) | −7,704 | -$121.3K | EDGAR |
| 2017-05-03 | Acorda Therapeutics, Inc. (ACOR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-03-03 | Acorda Therapeutics, Inc. (ACOR) Delisted | Grant (A) | +4,600 | $0 | EDGAR |
| 2016-12-05 | Acorda Therapeutics, Inc. (ACOR) Delisted | Sell (S) | −443 | -$9.2K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.